[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

![_Investor_Feed_ Avatar](https://lunarcrush.com/gi/w:24/cr:twitter::1825090112713285632.png) Investor Feed [@_Investor_Feed_](/creator/twitter/_Investor_Feed_) on x 6221 followers
Created: 2025-07-28 09:50:36 UTC

Astec Lifesciences Q1 FY25 Results: Loss Narrows, Revenue Rises 📊 | MCap XXXXXXXX Cr

- Standalone Loss before tax for Q1 FY25: ₹(3,305.64) Lakh vs ₹(6,166.80) Lakh in Q1 FY24
- Standalone Revenue from Operations for Q1 FY25: ₹9,108.21 Lakh vs ₹6,937.25 Lakh in Q1 FY24
- Standalone EPS for Q1 FY25: ₹(16.86) vs ₹(20.26) in Q1 FY24
- Consolidated Loss before tax for Q1 FY25: ₹(3,301.75) Lakh vs ₹(6,163.94) Lakh in Q1 FY24
- Current Ratio (Standalone) as of 30th June 2025: XXXX vs XXXX in Q1 FY24
- Debt Equity Ratio (Standalone) as of 30th June 2025: XXXX vs XXXX in Q1 FY24
- Operating Margin (Standalone) for Q1 FY25: -XXXXX% vs -XXXXX% in Q1 FY24
- Net Loss Margin (Standalone) for Q1 FY25: -XXXXX% vs -XXXXX% in Q1 FY24
- Company has only one reportable segment: Agrochemicals
- Board approved Rights Issue of 28,01,673 Equity Shares at ₹890 per share, aggregating to ₹249.35 Crore
- Credit Ratings: ICRA assigned '[ICRA] A1+' for short-term facilities and '[ICRA] AA-' for long-term facilities

Complete Source:

Disc: Information provided in this tweet can be inaccurate, verify through the source before making any investment decision.

Preview 👇 (First X out of XX pages)

![](https://pbs.twimg.com/media/Gw741XYagAIbeTg.jpg)

XXX engagements

![Engagements Line Chart](https://lunarcrush.com/gi/w:600/p:tweet::1949769451966283920/c:line.svg)

**Related Topics**
[tax bracket](/topic/tax-bracket)
[mcap](/topic/mcap)
[investment](/topic/investment)

[Post Link](https://x.com/_Investor_Feed_/status/1949769451966283920)